[{"orgOrder":0,"company":"Seagen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tucatinib","moa":"||Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Seagen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Seagen \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jules Bordet Institute","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Jules Bordet Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jules Bordet Institute \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Jules Bordet Institute \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Phase IV","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Alliance for Clinical Trials in Oncology","sponsor":"National Cancer Institute | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Alliance for Clinical Trials in Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alliance for Clinical Trials in Oncology \/ National Cancer Institute | Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Alliance for Clinical Trials in Oncology \/ National Cancer Institute | Pfizer Inc"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Genentech | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Genentech | Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Genentech | Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Trastuzumab Emtansine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Jules Bordet Institute

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Jules Bordet Institute

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Trastuzumab Emtansine is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Trastuzumab Emtansine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : F. Hoffmann-La Roche

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Kadcyla (trastuzumab emtansine) is a HER2 modulator, antibody-drug conjugate. It is being evaluated in phase 3 clinical trials for the treatment of HER2-positive early-stage breast cancer.

                          Product Name : Kadcyla

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          December 08, 2023

                          Lead Product(s) : Trastuzumab Emtansine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Kadcyla (ado-trastuzumab emtansine) is a HER2-targeted antibody-drug conjugate. It is being evaluated for the treatment of HER2-positive early-stage breast cancer With residual invasive disease after neoadjuvant treatment.

                          Product Name : Kadcyla

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          December 08, 2023

                          Lead Product(s) : Trastuzumab Emtansine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein and in combination with ado-trastuzumab emtansine is being developed in patients with HER2-positive metastatic or unresectable breast cancer.

                          Product Name : Tukysa

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 06, 2023

                          Lead Product(s) : Tucatinib,Trastuzumab Emtansine

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          MD Anderson Cancer Center

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          MD Anderson Cancer Center

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Trastuzumab Emtansine is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasm Metastasis.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          January 06, 2023

                          Lead Product(s) : Trastuzumab Emtansine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Genentech | Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Patients already treated with Trastuzumab may still have the disease and would require this therapy as the next step. The high cost of therapy is a barrier to availing this therapy and Ujvira bridges this need.

                          Product Name : Ujvira

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          May 24, 2021

                          Lead Product(s) : Trastuzumab Emtansine

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Trastuzumab Emtansine is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          May 19, 2021

                          Lead Product(s) : Trastuzumab Emtansine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Trastuzumab Emtansine is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          February 05, 2021

                          Lead Product(s) : Trastuzumab Emtansine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Approval is based on the study which evaluated the efficacy and safety of Kadcyla adjuvant therapy in patients with HER2-positive early breast cancer who did not have pathologic complete response following neoadjuvant therapy including Herceptin.

                          Product Name : Kadcyla

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          August 21, 2020

                          Lead Product(s) : Trastuzumab Emtansine

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Alliance for Clinical Trials in Oncology

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Alliance for Clinical Trials in Oncology

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Trastuzumab Emtansine is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          July 07, 2020

                          Lead Product(s) : Trastuzumab Emtansine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : National Cancer Institute | Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank